Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned ...

OTR Therapeutics may still be keeping its own pipeline under wraps, but Zealand Pharma has seen enough promise in the Chinese ...

Lumos Labs has obtained a clearance from the FDA for its popular Lumosity brain training platform, greenlighting a version of ...

After receiving word late last month that the FDA would not be issuing a 510(k) clearance to its cable-free electrocardiogram ...

Existing IPF treatments, including Boehringer’s recently approved Jascayd, slow disease progress rather than halt or reverse ...

The FDA has approved its first at-home, nondrug therapy for depression, a wearable brain stimulation headset developed by Flow Neuroscience.  | The FDA issued a green light that covers the wearable's ...

Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset ...

Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. | Rival ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...